Prostate Cancer
Conditions
Interventions
bone metastases:NA
lymphatic metastasis:NA
Both Bone and lymphatic metastasis:NA
none of metastasis:NA
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Male gender, (2) Expected lifespan =5 years; (3) Patients diagnosed with prostate cancer confirmed by biopsy prior to enrollment; (4) Patients with detailed and accurate recent reports of whole-body Magnetic Resonance Imaging (MRI) and whole-body Bone Scan (ECT) or Positron Emission Tomography/Computed Tomography (PET/CT), capable of determining whether the prostate cancer has metastasized and the specificity of the metastasis; (5) Willingness to accurately complete subject survey questionnaires; (6) Willingness to participate in long-term follow-up; (7) The patient himself or a direct relative authorized by the patient has signed the clinical trial informed consent form. Participants who meet all the inclusion criteria can be included in the study analysis.
Exclusion criteria
Exclusion criteria: (1) Concurrent other malignancies; (2) Recent radiation therapy, chemotherapy, or other treatments that could affect plasma samples; (3) Presence of other significant diseases that could interfere with study results, such as severe heart, liver, or kidney dysfunction; (4) Currently using or having recently used drugs that could affect the results of molecular biological analyses; (5) Presence of severe coagulation disorders or other hematologic diseases; (6) Poor compliance, unable to follow the study schedule. Participants meeting any one of the exclusion criteria will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Furin expression;PLS3 expression; | — |
Countries
China
Contacts
Public ContactYang Chenghua
Changhai Hospital
Outcome results
None listed